Clinical effects of CYP2D6 phenoconversion in patients with psychosis.

ABSTRACT:

Background

Pharmacogenetics is considered a promising avenue for improving treatment outcomes, yet evidence arguing for the use of pharmacogenetics in the treatment of psychotic disorders is mixed and clinical usefulness is under debate. Many patients with psychosis use multiple medications, which can alter the metabolic capacity of CYP enzymes, a process called phenoconversion. In clinical studies, treatment outcomes of drugs for psychosis management may have been influenced by phenoconversion.

Aim

Here we evaluate the impact and predictive value of CYP2D6 phenoconversion in patients with psychotic disorders under pharmacological treatment.

Method

Phenoconversion-corrected phenotype was determined by accounting for inhibitor strength. Phenoconversion-corrected

SUBMITTER: De Brabander EY 

PROVIDER: S-EPMC11528948 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature